FUNDAMENTAL AND CLINICAL EVALUATIONS OF BAY o 9867 (Ciprofloxacin) IN OBSTETRICAL AND GYNECOLOGICAL FIELD
スポンサーリンク
概要
- 論文の詳細を見る
A newly developed synthetic quinoline carboxylic acid antimicrobial agent, BAY o 9867, was investigated for its antibacterial activity, absorption, excretion, tissue penetration and clinical efficacy against obstetrical and gynecological infections, and the following results were obtained.<BR>1. The MICs of BAY o 9867 for 291 strains of 15 species of clinical isolates from obstetrical and gynecological fieldwereexamined.Theypeaked at 0.39 μg/ml in <I>S. aureus</I>, 0.2μg/ml in <I>S. epidemidis</I>, 0.78μg/ml in <I>E. faecalis</I>, ≤0.025 μg/ml in <I>E. coli</I>, 0.05 μg/ml in <I>K. pneumoniae</I>, 0.1 μg/ml in <I>P.aeruginosa</I>, ≤0.025 μg/ml in <I>C. freundii</I>, 0.39 μg/ml in <I>S. marcescens</I>, ≤0.025μg/ml in <I>Enterobacter</I> spp. and ≤0.025μg/ml in <I>Proteus</I> spp.The drug manifested an excellent antibacterial effect on both gram-positive cocci and gram-negative bacilli.<BR>2. Urinary excretion: The urinary excretion of BAY o 9867 were examined with cross over method (200mg, 400mg).The excretion rate within 8 hours after oral administration were 9.8-21.8% and dose response was recognised.<BR>3. Tissue penetration: The patients undergoing total hysterectomy were given 200mg of BAY o 9867 orally before the operation and the drug concentration was determined in various part of the resected organ and in the uterine arterial serum. The concentration in each tissue reached a peak after 1 hour 50 min.-3 hours 15 min. with the peak level of 1.26-1.80 μg/g, and these levels were maintained above MIC<SUB>80</SUB> of the drug for main causal organisms.<BR>4. Transference of the drug into maternal serum, umbilical cord serum and amniotic fluid were measured after oral alministration of 200mg. The transference were good and peak levehn umbilical cord serum was O.75 μg/ml and 1.83 μg/ml in amniotic fluid.These concentrations exceeded most of MICs of the main causal bacteria.<BR>5. Clinical results: BAY o 9867 was given to 61 cases of obstetrical and gynecological infections with a daily dose of 400-600mg and 90.2% of clinical efficacy and 88.7% of bacteriological response were obtained.No side effects were observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.